Protagonist Therapeutics names Thomas P. O'Neil CFO
Mr. O’Neil was previously the CFO of publicly traded agricultural biotechnology firm, Arcadia Biosciences.
Prior to joining Arcadia, Mr. O’Neil was the CFO of Sorbent Therapeutics, Inc. He has held executive-level positions with ChemGenex Pharmaceuticals, a publicly traded Australian-U.S. company, and biotechnology firms Nodality and HX Diagnostics, as well as finance roles with Monogram Biosciences, Inc., a publicly traded U.S. company.
Mr. O’Neil’s experience includes initial public offerings, oversight and management of equity and debt financings, mergers and acquisitions, collaborations, and investor relations. ■